

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE
CONVEYING PARTY DATA	
Name	Execution Date
Fox Chase Cancer Center	09/19/1996
RECEIVING PARTY DATA	
Name:	National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), U.S. Government
Street Address:	NIH Division of Extramural Inventions and Technology Resources (DEITR)
Internal Address:	6705 Rockledge Drive, Suite 310, MSC 7980
City:	Bethesda
State/Country:	MARYLAND
Postal Code:	20892-7980
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	08353700
CORRESPONDENCE DATA	
Fax Number:	(301)480-0272
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Email:	edison@nih.gov
Correspondent Name:	Director, DEITR
Address Line 1:	NIH, 6705 Rockledge Drive, Suite 310
Address Line 2:	MSC 7980
Address Line 4:	Bethesda, MARYLAND 20892-7980
NAME OF SUBMITTER:	Director, DEITR, NIH
Total Attachments: 1 source=08353700-p0001 - p0002#page2.tif	

FOX CHASE CANCER CENTER

LICENSE TO THE UNITED STATES GOVERNMENT

This instrument confers to the United States Government, as represented by the Department of Health and Human Services, a nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced on its behalf throughout the world the following subject of invention. This license will extend to all divisions or continuations of the patent application and all patents or reissues which may be granted thereon:

Invention Title: Nucleic Acid Encoding a Transiently Expressed Kinetochores Protein and Methods of Use


Lead Inventor(s): Timothy J. Yen, Jerome B. Rattner

U.S. Patent Application Serial No.: 08/353,700 Filed: 12/9/94

Countries (if other than United States): PCT/US95/16216

This subject invention was conceived or first actually reduced to practice in performance of a government-funded project, National Institutes of Health No. NIH GM 44762 & NIH CA 06927. Principal rights to this subject invention have been left with the Fox Chase Cancer Center, subject to the provisions of 37 CFR 401 and 45 CFR 8.

Signed:



Typed Name:

Patricia Harsche
Vice President,
Business Development & Regulatory Affairs

Dated:

September 19, 1996